Biocon Biologics receives Health Canada approval for Yesafili

The approval is based on a comprehensive package of analytical, nonclinical, and clinical data

Dr. Lal PathLabs strengthens its genomics capabilities with Illumina's NovaSeq X Series

The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability

Biocon concludes a Rs 4,500 crore equity fundraise through QIP

The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures

Sigachi Industries gets ToR approval for API and specialty chemicals manufacturing facility in Andhra Pradesh

The project will be instrumental in enhancing the company's API manufacturing capacity and global reach

Aayush Wellness to form subsidiary in Singapore to drive Southeast Asia expansion

This strategic expansion marks a significant step in the company's global growth strategy

AstraZeneca’s fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia

AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations

Zydus to acquire Agenus’ US manufacturing facilities, forays into global biologics CDMO business

Biocon gets approval for diabetes drug Liraglutide in India

The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus

SeQuent–Viyash merger receives stock exchange approvals; NCLT filing underway

QMS Medical Allied Services posts 134.36% jump in consolidated PAT in Q4 FY25

Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25